Categories
Cipla Limited — Updates, 23-04-2026: General Updates
23-04-2026 · 09:48 am
Cipla's US subsidiary gains USFDA approval for the first AB-rated generic of Ventolin® HFA. This major win strengthens its respiratory segment, targeting a ~$1.5 billion US market. Launch expected H1 FY26-27.
No comments yet. Be the first to comment!